<DOC>
	<DOCNO>NCT00193102</DOCNO>
	<brief_summary>The lack non-overlapping toxicity two drug , ease oral drug administration , possibility antitumor synergy make exploration combination regimen attractive woman previously treat metastatic breast cancer . This phase II trial perform collaboration Minnie Pearl Cancer Research Network , multicenter , community-based clinical trial group .</brief_summary>
	<brief_title>Thalidomide Combination With Capecitabine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Thalidomide + Capecitebine</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic breast cancer confirm biopsy Measurable evaluable disease Females &gt; 18 year Able perform activity daily live minimal assistance Life expectancy &gt; 3 month Adequate bone marrow , liver kidney function All patient must give write informed consent order participate . You participate study follow apply : Women pregnant lactating . Received 3 prior chemotherapy regimen metastatic setting . Received continuous infusion 5fluorouracil lasting &gt; 120 hour . Received thalidomide capecitabine last prior regimen . Preexisting moderate severe neuropathy Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>